SCHEMBL2908989

SCHEMBL2908989

COc1ccc(-c2ccc(C(c3c[nH]nc3-c3ccco3)N3CCN(C(=O)OC(C)(C)C)CC3)cc2)cc1

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.44
NPC1 O15118 1/20 0.44
MEN1 O00255 2/20 0.42
HTT P42858 3/20 0.42
ALDH1A1 P00352 3/20 0.42
TSHR P16473 1/20 0.42
SMN1; SMN2 Q16637 1/20 0.42
GPR119 Q8TDV5 2/20 0.41
KDM4E B2RXH2 1/20 0.41
MAPT P10636 1/20 0.41
ABCB1 P08183 1/20 0.39
ABCG2 Q9UNQ0 1/20 0.39
ADORA2A P29274 2/20 0.39
ADORA1 P30542 1/20 0.39
CYP3A4 P08684 2/20 0.39
CYP3A5 P20815 2/20 0.39
CACNA2D1 P54289 2/20 0.38
CACNA1B Q00975 2/20 0.38
CACNB1 Q02641 2/20 0.38
CACNA1C Q13936 2/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2902713 0.91 CYP3A4 (0.42) NPC1ALDH1A1TSHRGPR119KDM4E
SCHEMBL2902229 0.89 SMN1; SMN2 (0.47) KMT2ANPC1MEN1HTTALDH1A1
SCHEMBL2908049 0.89 ALDH1A1 (0.46) KMT2ANPC1MEN1HTTALDH1A1
SCHEMBL2904791 0.87 CYP3A4 (0.42) NPC1ALDH1A1GPR119KDM4EABCB1
SCHEMBL2901965 0.87 SCD5 (0.42) NPC1HTTALDH1A1GPR119KDM4E
SCHEMBL2901677 0.79 MAPT (0.39) KMT2ANPC1MEN1HTTALDH1A1
SCHEMBL2905980 0.78 ALDH1A1 (0.42) NPC1ALDH1A1TSHRKDM4EMAPT
SCHEMBL2905283 0.77 ALDH1A1 (0.52) KMT2ANPC1MEN1HTTALDH1A1
SCHEMBL31023690 0.76 ALDH1A1 (0.58) KMT2ANPC1MEN1HTTALDH1A1
SCHEMBL2910374 0.75 ALDH1A1 (0.41) KMT2ANPC1HTTALDH1A1TSHR

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP claimed
EP-1611107-B1 1,3,4-SUBSTITUTED PYRAZOLES FOR USE AS 5-HT RECEPTOR ANTAGONISTS IN THE TREATMENT OF PSYCHOSES AND NEUROLOGICAL DISORDERS MERCK PATENT GMBH (DE) 2010-08-18 EP disclosed
US-7566709-B2 1,3,4-Substituted pyrazoles as 5-HT receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2009-07-28 US disclosed
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders MERCK PATENT GMBH (DE) 2007-05-10 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070105871-A1 1,3,4-Substituted pyrazoles as 5-ht receptor antagonists for the treatment of psychoses and neurological disorders HTR1A, HTR1D, HTR5A KMT2A 2510/4885NPC1 1748/4885MEN1 1857/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.